|
|
|
Insider
Information: |
Altshuler David |
Relationship: |
EVP, Chief Scientific... |
City: |
Cambridge |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
1 |
|
Direct
Shares |
25,813 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$11,436,450 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
25,813 |
|
|
Total
Value |
$11,436,450 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Chief Scientific... |
2024-05-15 |
25,813 |
2014-07-31 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
157 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 4 of 7
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-11-15 |
4 |
AS |
$163.75 |
$16,375 |
D/D |
(100) |
39,113 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-02-02 |
4 |
AS |
$165.24 |
$298,330 |
D/D |
(1,796) |
49,761 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2019-05-15 |
4 |
AS |
$165.41 |
$15,052 |
D/D |
(91) |
31,553 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-11-05 |
4 |
AS |
$172.08 |
$400,946 |
D/D |
(2,330) |
39,113 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-08-03 |
4 |
AS |
$174.20 |
$405,886 |
D/D |
(2,330) |
39,113 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-08-02 |
4 |
AS |
$174.59 |
$313,564 |
D/D |
(1,796) |
39,113 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-11-02 |
4 |
AS |
$175.36 |
$314,947 |
D/D |
(1,796) |
39,113 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2019-02-11 |
4 |
AS |
$179.46 |
$5,939,188 |
D/D |
(32,956) |
37,177 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-08-28 |
4 |
AS |
$181.89 |
$386,516 |
D/D |
(2,125) |
39,113 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-11-07 |
4 |
AS |
$181.89 |
$386,516 |
D/D |
(2,125) |
39,113 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-07-16 |
4 |
AS |
$182.00 |
$4,254,250 |
D/D |
(23,375) |
39,113 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2019-08-19 |
4 |
AS |
$186.37 |
$2,329,976 |
D/D |
(12,501) |
31,553 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2021-11-15 |
4 |
AS |
$186.80 |
$6,365 |
D/D |
(34) |
33,589 |
0 |
% |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2019-02-19 |
4 |
AS |
$186.81 |
$1,051,716 |
D/D |
(5,624) |
31,553 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2019-11-25 |
4 |
OE |
$187.53 |
$733,242 |
D/D |
3,910 |
35,463 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2020-05-12 |
4 |
OE |
$187.53 |
$244,539 |
D/D |
1,304 |
30,206 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2022-08-08 |
4 |
OE |
$187.53 |
$244,539 |
D/D |
1,304 |
37,381 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2022-11-07 |
4 |
OE |
$187.53 |
$244,352 |
D/D |
1,303 |
37,380 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2023-02-06 |
4 |
OE |
$187.53 |
$244,539 |
D/D |
1,304 |
69,949 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2019-02-04 |
4 |
AS |
$189.19 |
$780,598 |
D/D |
(4,126) |
39,113 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2019-01-22 |
4 |
AS |
$193.48 |
$411,145 |
D/D |
(2,125) |
39,113 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2019-10-22 |
4 |
AS |
$194.37 |
$713,144 |
D/D |
(3,669) |
31,553 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-10-01 |
4 |
AS |
$194.62 |
$475,846 |
D/D |
(2,445) |
39,113 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2019-01-18 |
4 |
AS |
$194.62 |
$238,020 |
D/D |
(1,223) |
39,113 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2019-11-06 |
4 |
AS |
$196.08 |
$241,189 |
D/D |
(1,223) |
31,553 |
0 |
- |
|
157 Records found
|
|
Page 4 of 7 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|